首页> 外文期刊>British Journal of Dermatology >Treatment of hereditary palmoplantar keratoderma: a review by analysis of the literature
【24h】

Treatment of hereditary palmoplantar keratoderma: a review by analysis of the literature

机译:治疗遗传性棕榈腭角耳昔粒症:文献分析综述

获取原文
获取原文并翻译 | 示例
           

摘要

Background No specific or curative therapy exists for hereditary palmoplantar keratoderma (hPPK), which can profoundly alter patient quality of life, leading sometimes to severe functional impairment and pain. The rarity and the aetiological diversity of this group of disorders can explain the difficulty in comparing the efficacy of available treatments. Objectives To review the different treatments tried in patients withhPPKsince 2008, their efficacy and safety, with an evaluation of the various therapeutic modalities that can be used to treathPPK. Methods We undertook a comprehensive review of the literature data published since 2008. Results Only a few case series and individual case reports were identified. Topical (emollients, keratolytics, retinoids, steroids) and systemic treatments (mostly different retinoids), often combined, are used to relieve symptoms. Oral retinoids appear to be the most efficient treatment, but not in allPPKforms, and with variable tolerance. New targeted treatments, according to the specific mechanisms ofhPPK, appear promising for the future. Conclusions More studies using robust methodology and involving larger cohorts of well-characterized patients (phenotype-genotype) are necessary and should be prioritized by structured networks, such as the European Network for Rare Skin Diseases (ERN-Skin), with the aim of better management of patients with rare skin diseases.
机译:背景遗传性掌跖角化病(hPPK)没有特异性或治疗性治疗,它可以深刻改变患者的生活质量,有时会导致严重的功能损害和疼痛。这组疾病的罕见性和病因多样性可以解释比较现有治疗方法疗效的困难。目的回顾自2008年以来HPPK患者尝试的不同治疗方法、疗效和安全性,并评估可用于治疗HPPK的各种治疗方式。方法对2008年以来发表的文献资料进行全面回顾。结果仅发现少数病例系列和个别病例报告。局部治疗(润肤剂、角膜溶解剂、维甲酸、类固醇)和全身治疗(主要是不同的维甲酸)通常结合使用,以缓解症状。口服维甲酸似乎是最有效的治疗方法,但并非所有PPKforms都有效,而且耐受性也不尽相同。根据HPK的具体机制,新的靶向治疗在未来似乎很有希望。结论有必要进行更多的研究,采用稳健的方法,让更多具有良好特征的患者(表型-基因型)参与进来,并通过结构化网络(如欧洲罕见皮肤病网络(ERN-Skin))优先考虑,以便更好地管理罕见皮肤病患者。

著录项

  • 来源
    《British Journal of Dermatology》 |2021年第3期|共8页
  • 作者单位

    Paris Ctr Univ Dept Dermatol Reference Ctr Genodermatoses MAGEC Necker Enfants Malad APHPS ERN;

    Maastricht Univ Dept Dermatol Med Ctr Maastricht Netherlands;

    Paul Sabatier Univ ERN Skin Larrey Hosp Dept Dermatol Ctr Reference Malad Rares Peau Toulouse;

    Barts Hlth NHS Trust Royal London Hosp ERN Skin Dept Dermatol London England;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 皮肤病学与性病学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号